Open labelled, single arm, interventional study of Apremilast in childhood dermatosis
Not Applicable
Completed
- Conditions
- Health Condition 1: L639- Alopecia areata, unspecifiedHealth Condition 2: L209- Atopic dermatitis, unspecifiedHealth Condition 3: L439- Lichen planus, unspecifiedHealth Condition 4: L409- Psoriasis, unspecifiedHealth Condition 5: L80- Vitiligo
- Registration Number
- CTRI/2022/03/041201
- Lead Sponsor
- CUTIS Academy of Cutaneous Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1.Children between age of 6-17 years
2.Confirmed dermatological diseases (psoriasis, vitiligo, alopecia areata, atopic dermatitis)
3.Both male and female children will be recruited
4.Parents willing to provide written informed consent
Exclusion Criteria
1.History of any chronic systemic disease
2.History of any congenital anomaly
3.Patients with active infection
4.Participated in a clinical trial in last 90 days
5.Parents not willing to provide written informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect assessed in terms of decrease in the disease activity clinically and/or dermoscopically.Timepoint: After 4 months
- Secondary Outcome Measures
Name Time Method ï?· Patient satisfaction with treatment will be assessed based on a Grading questionnaire <br/ ><br>ï?· Patient compliance will be assessed based on completed patient diary and compliance <br/ ><br>assessment during study visits <br/ ><br>ï?· Safety will be assessed based on the adverse reactions reported during the study <br/ ><br>period.Timepoint: After 4 months